Wells Fargo initiated coverage of Claritev with a rating of Equal Weight and set a new price target of $33.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2026 | $43.00 | Buy | Guggenheim |
| 1/9/2026 | $33.00 | Equal Weight | Wells Fargo |
| 10/21/2025 | $74.00 | Neutral → Buy | Citigroup |
| 5/29/2025 | $44.00 | Neutral → Overweight | Piper Sandler |
Guggenheim initiated coverage of Claritev with a rating of Buy and set a new price target of $43.00
Wells Fargo initiated coverage of Claritev with a rating of Equal Weight and set a new price target of $33.00
Citigroup upgraded Claritev from Neutral to Buy and set a new price target of $74.00
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors at the following investor events in March 2026: Mizuho Virtual Healthcare Technology Conference 2026 – Thursday, March 5, 2026 - 1x1 meetings hosted virtually Q&A Webcast Hosted by Nephron Research – Friday, March 6, 2026 at 11 a.m. ET. (Webcast details below) Barclays 28th Annual Global Healthcare Conference – Wednesday, March 11, 2025, at the Loews Miami Beach Hotel, Miami Beach, FL - 1x1 meetings To listen to the Q&A we
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, will host its 2026 Investor Day on Monday, March 16, 2026 at the New York Stock Exchange. The event will feature presentations by members of Claritev's management team discussing the company's long term growth strategy, vertical markets, product roadmap, and financial outlook, along with conversations with a number of clients and partners. The event and a live webcast will begin at 1:00 p.m. ET. Registration for the webcast can be found at https://www.claritev.com/investor-day-2026/. An archive of the webcast wi
Q4 2025 Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%) Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024) Full-year 2026 Guidance initiated: Revenue range of $980 million to $1 billion Free cash flow of $0 million to $10 million Capital expenditures of $160 million to $170 million Company Board of Directors approves $75 million, five-year share repurchase program Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insigh
8-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
Third annual report highlights the company's commitment to social and environmental stewardship Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the publication of its 2024 Corporate Responsibility Report. The 2024 report showcases the Company's strategic momentum in advancing its sustainability priorities during a pivotal year of transformation. The report emphasizes Claritev's continued focus on managing, tracking and disclosing its social and environmental performance, reinforcing its commitment to accountability and responsible
Strategic leadership and operational collaboration underscore Claritev's commitment to growth in the Middle East and international business development outside the US Claritev Corporation ("Claritev") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it is deepening its investment in the Middle East North Africa ("MENA") region and the market outside the United States with the appointment of new regional leadership and a strategic operational collaboration. These moves reflect Claritev's continued focus on expanding its footprint and delivering localized, high-impact healthcare technology soluti
HOLLYWOOD, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Great Speech, a national leader in virtual speech therapy, is proud to announce a new agreement with Claritev, formerly known as MultiPlan (NYSE:CTEV), a technology and data insights company focused on making healthcare more affordable, transparent and fair for all. This network participation agreement marks a major step forward in expanding access to high-quality, convenient, and personalized speech therapy services for individuals and families nationwide. Great Speech's innovative teletherapy services will now be available to health plan members accessing Claritev's MultiPlan and PHCS Networks. The initiative aims to eliminate traditio
Q4 2025 Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%) Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024) Full-year 2026 Guidance initiated: Revenue range of $980 million to $1 billion Free cash flow of $0 million to $10 million Capital expenditures of $160 million to $170 million Company Board of Directors approves $75 million, five-year share repurchase program Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insigh
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 23, 2026, and hold a conference call at 4:30 pm Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to the following
– Q3 2025 Revenues of $246.0 million grew 6.7% compared to Q3 2024 – Net Loss of $69.8 million – Adjusted EBITDA of $155.1 million increased 9.5% compared to Q3 2024 (Adjusted EBITDA Margin of 63.1% versus 61.5% in Q3 2024) – Claritev raises full-year 2025 revenue and Adjusted EBITDA guidance Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2025. "We declared 2025 would be the Year of the Turn at Claritev. Our third quarter results and increased full year guidance demonstrate that w